Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Kang'ai Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Guangdong Provincial Hospital of Chinese Medicine. It is designed to "strengthen the body's resistance" (Fuzheng) and exert anti-tumor effects (Kang'ai). In clinical research, it is specifically investigated for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients classified under the "phlegm-damp" syndrome in TCM. The decoction is often used as an adjuvant therapy alongside immune checkpoint inhibitors, such as PD-1 inhibitors, to enhance efficacy and potentially mitigate side effects. Its mechanism likely involves immunomodulation and regulation of the tumor microenvironment, though specific molecular targets for the complex mixture are not typically defined in a single-target pharmacological sense.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuzheng Kang'ai Decoction (Guangdong Provincial Hospital of Traditional Chinese Medicine).